Madrigal Pharmaceuticals, Inc.
MDGL
Rank in Stocks
#1936
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Share Price
$469.34
Market Cap
$10.84B
Change (1 day)
0.39%
Change (1 year)
9.15%
Country
US
Trade Madrigal Pharmaceuticals, Inc. (MDGL)
Category
Healthcare
Stock price history for Madrigal Pharmaceuticals, Inc. (MDGL)
Highest end of day price: $473.22 on 2026-10-01
Lowest end of day price: $322.31 on 2007-02-01
Lowest end of day price: $322.31 on 2007-02-01
Stock price history of Madrigal Pharmaceuticals, Inc. from 2007 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -11.55% |
| 2025 | 85.56% |
| 2024 | 36.19% |
| 2023 | 46.99% |
| 2022 | 95.20% |
| 2021 | -32.68% |
| 2020 | 16.63% |
| 2019 | -6.63% |
| 2018 | 32.71% |
| 2017 | 414.16% |
| 2016 | 26.67% |
| 2015 | -87.18% |
| 2014 | -42.14% |
| 2013 | -44.12% |
| 2012 | 87.26% |
| 2011 | -19.61% |
| 2010 | 10.34% |
| 2009 | 1.71% |
| 2008 | -25.83% |
| 2007 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $518.71 | 21.68% |
US
|
|
| $247.50 | 800.33% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $886.30 | 6.17% |
NL
|
|
| $752.87 | 7.40% |
CH
|
